In the subset of depressed patients who exhibit elevated inflammatory cytokines, such as IL-6, IL-17, and TNF-α, targeted use of monoclonal antibodies against these cytokines can result in reduced anhedonia and overall depression severity. The gene discussed is IL17A; the disease is depressive symptom measurement.